Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bristol Getting Eagerly Awaited First-Line Opdivo Lung Data Earlier Than Expected

Executive Summary

Bristol-Myers Squibb Co. is moving up the timing on its eagerly awaited CheckMate-026 first-line lung cancer trial of Opdivo, with data now expected in the third quarter – earlier than prior guidance.


Related Content

Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
Immuno-Oncology's Next Wave: Key Targets And Emerging Players
Merck Is Finding PD-L1 Testing Is Helping Keytruda
BMS: Sales For Opdivo Are Flying High


Related Companies